Our team

The foundation upon which Pure Biologics is built comprises a group of exceptionally talented and energetic people who pursue every project and idea with passion. Our employees constitute a diverse and multidisciplinary team with extensive experience gained in domestic and international institutions alike. Each and every person who conceptualizes ideas and actively participates in implemented projects, ultimately determines the stability of the team and its full engagement in achieving set goals. Highly qualified staff, years of experience and a focus on effective cooperation enable us to reach successive milestones of R&D projects and to execute contracted research activities.

A scientist and entrepreneur. Filip acquired 15+ years of research experience, both in Poland and the USA, and over 10 years of experience in building start-ups. He received his Ph.D. in biochemistry from the University of Wroclaw in the Department of Protein Engineering. Next, he trained at the Institute of Molecular Medicine at Health Science Center in Houston, USA, in the laboratory of Nobel Prize laureate Professor Ferid Murad, where he investigated signaling proteins related to cardiovascular diseases. He obtained his executive MBA diploma at the Polish-American School of Business. Filip has broad experience in biotechnology-related businesses and is involved in many R&D projects associated with the development of new drugs and medical devices.

dr. Filip Jeleń, MBA
Co-founder, Chairman of the Board

Romuald Harwas graduated from the Faculty of Management at the Cracow University of Economics, majoring in accounting. He has several years of experience in finance. Romuald began his career from the position of financial analyst, was a management accountant, financial controller and then CFO and a board member of limited companies. In Poland, he worked at TVN, Luxmed and Synektik. Romuald spent more than six years abroad, working for among others, Australian syndicate Bradken. He has led transition processes of companies from NewConnect to the main market of the WSE and cooperated with various investment funds. Romuald is a specialist in management, accounting and economic analysis.

Romuald Harwas
Vice Chairman of the Board, Chief Financial Officer

 

 

 

 

 

Board of Directors information

Marta Wawrzyniak is a graduate of biotechnology at the University of Wrocław and Executive MBA studies at the Polish-American School of Business. At Pure Biologics, first she carried out projects in the areas of ​​antibody development, protein production and purification, and cell biology, before taking the role of project manager. Marta originated the PureSelect2 platform for antibody selection and has contributed to concepts driving the company’s drug development projects implemented by the company. Currently, Marta is the Operations Director. Being responsible for coordinating work of the company’s internal departments, she is involved in strategic areas of the company’s development, including raising funds for research projects, team building, internal improvement programs and the organization of an efficient work environment.

Marta Wawrzyniak, MBA
Chief Operating Officer

Przemysław Jurek graduated in biotechnology from the University of Wrocław. He also completed postgraduate studies in Industrial Pharmacy at the Jagiellonian University and Executive MBA studies at the Polish-American School of Business. Przemysław participated in a research internship in the group of Professor Kurt Gothelf at iNano at the University of Aarhus (Denmark). His main areas of expertise include aptamers, analysis of intermolecular interactions and early stages of drug development. He earned his Ph.D. on the basis of research and technology that he developed for Pure Biologics. Przemysław originated the platform for selection of chemically modified aptamers – PureApta. In the company, he is responsible for the research and development strategy, project portfolio management and coordinating the work of project managers.

dr. Przemysław Jurek, MBA
Director of Research & Development

An expert in the field of capital transactions, commercial law, business transformation, finance and banking and management. As a long-term manager of the Lower Silesian Brokerage, he managed publicly traded private equity funds, handled business transformations, issuing projects and IPOs of technological companies listed in the ATS and on the WSE.

Andrzej Trznadel
Chairman of the Supervisory Board

Prof. dr hab. Julia Bar is a head of the Immunopathology and Molecular Biology Division of Wroclaw Medical University. She specializes in immuno-oncology, cancer biology and in regenerative medicine and tissue engineering experimental research. She conducts research on cancer cell resistance to chemotherapy and on stem cell-based biological implants. Her scientific achievements include two patents, several dozen research papers and almost two hundreds conference presentations.

prof. dr. hab. Julia Bar

Dr Tadeusz Wesołowski has obtained his PhD in the field of technical sciences at the Warsaw University of Technology. He has had many years of experience in implementing private investments in the new technologies, as well as an extensive professional experience in the health care sector. The founder of Prosper S.A. which after merging with Torfarm S.A. since 2009 has been a member of NEUCA S.A. Capital Group – the leader of the pharmaceutical distribution market in Poland. He is a member of supervisory boards of companies listed on the WSE. He has also been involved in Venture Capital funds: Inovo and Experior.

dr. Tadeusz Wesołowski

Dr hab. Mariusz Czekala is a professor and lecturer at the WSB University in Wroclaw. He is a recognized expert in the field of quantitative disciplines i.e. money theory in time, elements of statistics and econometrics, fundamental and technical analysis, portfolio analysis, and stock quotation systems. He specializes in building econometric models for valuation of capital companies and investments. He published a number of scientific papers and monographs, including in the field of fundamental and technical analysis of financial instruments, effectiveness of investment funds and financial risk protection instruments.

dr. hab. Mariusz Czekała

Andrzej Kierzkowski graduated from the University of Wroclaw majoring in computer science and postgraduate studies in publishing at the University of Warsaw. Publisher, IT specialist, individual investor. Co-founder and for many years a member of the Management Board of companies associated with the publishing market, including Helion S.A. and helion.pl. Has experience in building start-ups and M&A. For many years, he has managed finances of companies, especially in the first stages of development.

Andrzej Kierzkowski

 

 

 

 

 

Supervisory Board information

Professor Jacek Otlewski is an experienced biochemist, biophysicist and molecular biologist, a researcher of the structure and function of proteins. For many years, he has been developing phage display technology for antibodies and other protein structures. His research interests are related to targeted therapy and the development of conjugates of therapeutic proteins and cytostatics in the treatment of cancer. He supervised several dozens of doctorates, authored over 150 publications and several patents. He is a member of the Polish Academy of Sciences, European Molecular Biology Organization and Academia Europaea. Since 1994, he is the head of the Protein Engineering Department and in the years 2006-2012 he served as dean of the Faculty of Biotechnology of the University of Wroclaw.

prof. dr. hab. Jacek Otlewski

Dr. Waldemar Priebe is Professor of Medicinal Chemistry at the Department of Experimental Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, in Houston (USA). His career developed in the translational space between research on novel approaches to drug design, preclinical studies, as well as industry and business. Waldemar Priebe is a cofounder of numerous companies, a few of which are in the NASDAQ index. He has also served as a consultant to numerous pharmaceutical companies. Dr. Priebe’s research focuses on metabolic pathway inhibition in cancer. Results and inventions of Dr. Priebe are published in more than 200 scientific articles and protected by over 50 patents.

dr. Waldemar Priebe

Dr. Radosław Zagożdżon graduated from the Faculty of Medicine of the Medical University of Warsaw. He was a postdoctoral fellow and worked at Beth Israel Deaconess Medical Center of the Harvard Medical School in Boston (USA) and at University College Dublin in Ireland. Since 2017, he has been the head of the Department of Clinical Immunology at the Institute of Transplantation of the Medical University of Warsaw, at the same time working as a physician in the Department of Immunology, Transplantology and Internal Diseases of the Infant Jesus Clinical Hospital. He is also a scientific consultant in the Department of Bioinformatics at the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences. Dr Zagożdżon has several years of medical and scientific experience, including conducting animal research to study the effects of new compounds on the immune system and in cancer.

dr. hab. Radosław Zagożdżon

Professor Mayer studied chemistry at the University of Munich and obtained his doctoral degree in the field of biochemistry at the University of Bonn. Since 2010, he has been a head of a research group and professor of chemical biology and chemical genetics at the University of Bonn, where he investigates use of aptamers in basic and applied research. His group develops aptamers for new therapeutic and diagnostic approaches. He is a cofounder of NascaCell GmbH and founding director of the Center for Aptamer Research and Development in Bonn. Prof. Günter Mayer is an author of more than 100 scientific publications and a leader of international projects in the field of aptamers.

prof. Günter Mayer

Professor Bogusław Paradowski is a specialist in neurology with several years of experience. He works among others in the Neurology Clinic at the University Clinical Hospital in Wrocław, where he is a deputy head of the clinic. His scientific interests encompass demyelination diseases, including multiple sclerosis, vascular diseases and dementia. Thanks to his initiative, nine medical centers were established in Lower Silesia, where patients suffering from multiple sclerosis are treated with modern I-line methods. For over 20 years, professor Paradowski has been Lower Silesian Voivodeship chief consultant in the field of neurology. Since 2017, he has held the position of associate professor at the University of Medical Sciences in Wroclaw.

dr. hab. Bogusław Paradowski

Professor Konrad Rejdak, M.D. is a specialist in neurology. He is head of the Department and Clinic of Neurology at the Faculty of Medicine at the Medical University of Lublin, and the president-elect of the Polish Society of Neurology. Professor Rejdak is also a member of the Scientific Panel of the European Academy of Neurology, as well as numerous scientific societies, both Polish and international (including the American Academy of Neurology, International League Against Epilepsy, ECTRIMS). He is also a voivodeship consultant in the field of neurology in the Lubelskie Voivodeship.

prof. dr. hab. Konrad Rejdak

Michał Piróg is a graduate from the University of Wroclaw, where he received his Ph.D. in the field of molecular physiology. During his graduate studies, he focused on embryology, specializing in developmental biology, genetics and cell physiology. Michał then worked as a scientist in Scotland, and later as an embryologist at a fertility clinic in Poland. For six years he was an embryology laboratory manager and a person responsible for keeping and archiving medical records. Proof of Michał’s knowledge and skills are supported by numerous certificates, such as an ISO 9001:2015 audit management diploma and an ESHRE Senior Clinical Embryologist certificate – the highest certificate in the field of human embryology.

dr. Michał Piróg
Laboratory Manager

Richard Fox received his Ph.D. in pathology at the University of Washington and went on to post-doctoral and faculty positions at the University of Washington and Fred Hutchinson Cancer Research Center. There he studied innate immunity and macrophage biology. Later he focused on primary HIV infection and curative measures employing gene based therapies. In addition to his roles in academia, Richard has held several senior leadership positions within industry in the infectious disease, rare disease and immuno-oncology landscapes – one of them being Director of Scientific and Medical Affairs (virology) at Merck. His skills range from basic science through designing, developing and executing research, including pre- and clinical phase studies, to medical and observational data development and management, and effective handling of collaborative relationships.

dr. Richard Fox
Director of Preclinical Development

Maciej Mazurek has been associated with the company since its foundation. He is a molecular biologist by training and has also finished “Executive MBA” studies at the Polish-American School of Business. Maciej has a dozen years of experience gained in Poland, as well as abroad (at the Medical College of Georgia, USA, and at Imperial College London, UK), taking part in several R&D projects, both as a researcher and as a project manager. He is an author of two patents and one patent-pending application. Maciej specializes in developing ideas, in acquiring public funds, and in monitoring business environments.

Maciej Mazurek, MBA
Director of Science and Innovation

Kinga is a microbiologist and geneticist, having completed her Ph.D. at the Institute of Immunology and Experimental Therapy of Polish Academy of Sciences. She broaden her scientific experience during a post-doctoral fellowship at the Institute for Molecular Biology in Houston and at the Wrocław University of Environmental and Life Sciences. Kinga is also a qualified executive, having a Polish-American MBA from Franklin University , Ohio and WSB University in Wrocław. Kinga also holds a certificate in PRINCE2 project management. Since 2010, she has managed both science and business projects. Between 2009 and 2013 she cooperated with the Wrocław Research Center EIT+, where she executed her original project – “Humanitarium” Science Center.

dr. Kinga Świtała-Jeleń, MBA
Director of Project Management

Michał Surma worked on his doctorate at the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden (Germany) and at the University of California in San Francisco (USA). Cell biology, lipids and lipidomics are his major specialties, but he is also knowledgeable in laboratory operations, high-throughput projects, QM, GLP and other biotech-related activities. In 2012, Michał, along with professor Kai Simons and colleagues, commercialized their lipidomic analysis technology and started a biotech company – Lipotype GmbH, where Michał was Head of Analytical Services, responsible for commercial operations and customer service. Later on, he worked at the Łukasiewicz Research Network – PORT Polish Center for Technology Development as Core Facilities Leader, coordinating the work of six laboratories.

dr. Michał Surma
Business Development Manager

After completing her undergraduate studies in philology, Marta Rot pursued postgradute education in Labour Law and Social Law at the Faculty of Law, Administration and Economics at the of University of Wrocław. During this time she also completed the Human Resources Management course at the Wrocław University of Economics. She is a certified business coach, a consultant on organizational efficiency, an Assessment & Development Center assessor, and a manager with more than 20 years of experience in HR. Marta gained her expertise at large corporate structures (Telefonia Dialog, Netia), and at a research & development institution operating in the area of bio- and nanotechnology. She is a lecturer of postgraduate courses for HR Business Partners at Wrocław University of Economics and she holds ongoing collaborations with the WSB University in Wrocław, the University of Wroclaw, and the Wrocław University of Science and Technology.

Marta Rot
Director of HR

Robert obtained his doctorate at the Wroclaw University of Science and Technology, where he investigated protein folding processes. After his doctorate, Robert worked at the Adam Mickiewicz University in Poznan, University of Helsinki (Finland) and the University of Leeds (England). He then further expanded his knowledge and experience in cloning, expression, purification as well as protein modification and analysis at the EMBL in Hamburg, BESSY in Berlin (Germany), University Hospital in Lund (Sweden) and the ESRF in Grenoble (France). He has participated in several projects related to production and structural analysis of proteins. He is a co-author of the project on commercial use of protein lattices in structural research. He is an awardee of the Pol-Postdoc II competition and was a member of the Crystallographic Committee of the Polish Academy of Sciences from 2007-2010.

dr. Robert Kołodziejczyk
Research Group Leader - Recombinant Proteins

Jakub is a graduate of biotechnology from the Jagiellonian University. During his undergraduate studies he completed several international research internships (IGMM-Montpellier, CNIC-Madrid, A.I. Virtanen Institute-Kuopio). Jakub then relocated to Montpellier (France) for doctoral studies, where he discovered new functions of Twist oncogenes, demonstrating their protective properties during oxidative and hypoxic stress. He then continued research in the field of oxidative stress and its influence on mitotic arrest at the University of Dundee (UK). Throughout his research projects, Jakub gained general knowledge in the field of molecular and cell biology, developing particular expertise in the design of cell-based assays, production of viral vectors, gene expression analysis and live cell imaging.

dr. Jakub Kołodziejski
Research Group Leader - Cell and Molecular Biology

Originally from the USA, David began his career in protein chemistry by obtaining a B.Sc. in Biochemistry at San Francisco State University (USA). In Montréal (Canada) he then earned an M.Sc. in Biochemistry at Concordia University and his Ph.D. in Microbiology at McGill University. During this time, he focused heavily on using biophysical technologies to investigate protein-small molecule and protein-protein interactions alike. This led him to Berlin (Germany), where he performed postdoctoral research at the Max Delbrück Center for Molecular Medicine (MDC). At the MDC he obtained an MDC-GoBio Fellowship, allowing him to screen chemical libraries and to discover small molecule inhibitors of human lysine demethylase enzymes. During this time, he used X-ray crystallography and complementary biophysical technologies to further develop inhibitors for entry into preclinical testing programs.

dr. David Carter
Research Group Leader - Biophysics

Agnieszka earned her PhD at the Wrocław University of Science and Technology, where she discovered a JHBP gene promoter sequence and analyzed elements regulating its expression. During this time, she also worked at the Department of Clinical Immunology IITE PAS in Wrocław, where she developed and implemented assays for the diagnosis and monitoring of patients with myeloproliferative disorders, and who were undergoing blood transplants. Since 2009, Agnieszka has continued her scientific career at the University of Wrocław, focusing her research activities on changes in gene expression patterns that are related to carbohydrate metabolism in cells undergoing neoplastic transformations and in cells related to neurodegenerative disorders. In parallel, Agnieszka also completed postgraduate studies in research project management at the Adam Mickiewicz University in Poznan.

dr. Agnieszka Sok-Grochowska
Research Group Leader - Aptamers

Tomasz is a graduate of the Jagiellonian University in Kraków, where his training in research was supported by a START scholarship from the Foundation for Polish Science. Since 2011, he has focused on leveraging hybridoma and phage display technologies to discover new antibodies. Tomasz has also attained expertise in antibody engineering, in designing their effector functions, and in improving antibody stability. His work has contributed to the development of both diagnostic and therapeutic biomolecules alike and has led to four patents. Tomasz also discovered a new mechanism of post-translational proteolytic processing of mouse IgM and has elucidated structural determinants of mouse IgG3 oligomerization.

dr. Tomasz Klaus
Research Group Leader - Antibodies

Pure Biologics comprises a team of extremely talented and energetic people who pursue their goals with passion. Our team consists of employees with broad competences and extensive experience gained in research units from around the world.

Menu Close

We use cookies to give you the best browsing experience, site traffic analysis, and advertisement management.